Globus Medical Inc

Análisis de la acción Globus Medical Inc (GMED)

$76.710

-2.071 (-2.70%)Al cierre

Loading chart…
Máximo
79.950
Apertura
79.350
Precio medio ponderado por volumen
77.72
Volumen
1.94M
Capitalización
9.30B
Mínimo
76.490
Importe
150.80M
EV/EBITDA, TTM
9.09

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions.

Análisis de IA of Globus Medical Inc (GMED)

Mantener

Globus Medical Inc is currently trading at $76.71, which is below the average analyst price target of $85 from RBC Capital. The stock has a forward P/E ratio of 13.87, indicating it is relatively undervalued compared to its earnings potential. However, insider selling has increased by 389.20% recently, which raises concerns about the stock's short-term outlook. Therefore, while the long-term growth potential remains, the current market sentiment and insider activity suggest a cautious approach, leading to a hold recommendation.

Recomendaciones de analistas (13)

+31.66% de potencial alcista
Mantener
5 Comprar
7 Mantener
1 Vender
Actual: 76.71
Mínimo
87.00
Promedio
101.00
Máximo
114.00

RBC Capital

2026-10-01

Precio objetivo

$85

Superar al mercado

Wells Fargo

2026-08-07

Precio objetivo

$99

Sobreponderar

UBS

2026-07-28

Precio objetivo

$82

Neutral

Truist

2026-07-16

Precio objetivo

$100

Comprar

BMO Capital

2026-07-08

Precio objetivo

$94

Superar al mercado

Métricas de valoración

El PER previsto actual de Globus Medical Inc (GMED) es 13.87, frente a su media de 5 años de 23.36.

PER previsto

Infravalorado
Media 5A P/E
23.36
P/E actual
13.87
Sobrevalorada
28.91
Infravalorada
17.81

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
12.01
EV/EBITDA actual
9.09
Sobrevalorada
14.87
Infravalorada
9.16

Precio/ventas previsto

Valor razonable
Media 5A P/S
4.17
P/S actual
3.12
Sobrevalorada
5.62
Infravalorada
2.73

Escenarios de precio de Alphio AI para GMED

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%GMED

$74.60

Precio del escenario

B

Base

Base · 50%GMED

$69.01

Precio del escenario

B

Bajista

Bajista · 25%GMED

$65.33

Precio del escenario

Ballenas con GMED en cartera

B

Burgundy Asset Management Ltd.

+ Con en carteraGMED

+6.08%

Rentabilidad a 3 meses

A

American Capital Management, Inc.

+ Con en carteraGMED

+1.32%

Rentabilidad a 3 meses

R

Ruane, Cunniff & Goldfarb L.P.

+ Con en carteraGMED

+1.24%

Rentabilidad a 3 meses

N

Nationwide Fund Advisors

+ Con en carteraGMED

-1.49%

Rentabilidad a 3 meses

A

Antipodes Partners Ltd.

+ Con en carteraGMED

-1.82%

Rentabilidad a 3 meses

A

Anchor Capital Advisors LLC

+ Con en carteraGMED

-2.29%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-31 (ET)

08:30:00

Higgs Boson Health Acquired by Globus Medical

2026-08-26 (ET)

18:00:00

Globus Medical Acquires Higgs Boson Health

2026-05-07 (ET)

18:20:00

Company Reports Q1 Revenue of $759.85M, Beating Expectations

18:20:00

Company Reaffirms FY26 Revenue Guidance of $3.18B to $3.22B

Noticias

Preguntas frecuentes sobre GMED, respondidas por Alphio AI

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Globus Medical Inc is currently trading at $76.71, which is below the average analyst price target of $85 from RBC Capital. The stock has a forward P/E ratio of 13.87, indicating it is relatively undervalued compared to its earnings potential. However, insider selling has increased by 389.20% recently, which raises concerns about the stock's short-term outlook. Therefore, while the long-term growth potential remains, the current market sentiment and insider activity suggest a cautious approach, leading to a hold recommendation.

13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar